Mantle Cell Lymphoma Pathway & Targeted Therapy Simulator NCCN / Precision Oncology

Interactive t(11;14) translocation, CCND1/Cyclin D1 cell cycle dysregulation, and molecular targeted therapy engine

t(11;14) Molecular Pathway Visualizer

Status: t(11;14) Translocation Active
Chromosome IgH/CCND1 Axis
Cyclin D1/CDK4 Complex
BTK / BCR Survival Axis
BCL-2 Anti-Apoptotic Axis
Baseline Proliferation
0.142 /d
Inhibited Growth Rate
0.018 /d
G1/S Phase Inhibition
87.3%
Predicted Vol Reduction
88.5%

Targeted Pathway Inhibitor Workbench

Biomarker-Driven Selection
Patient Case Profile: 68yo Male | Stage III Mantle Cell Lymphoma
Biomarker Panel: t(11;14)(q13;q32) POS | Ki-67 Index: 35%
Cyclin D1 Overexpression: 4.8x Fold Baseline
Ki-67 Index (%) 35%
Simulation Days 180d
Cell Cycle Phase Ring
Population Trajectory (180d)

Oncology Evidence Matrix: NCCN Guidelines vs. Unproven Claims

Current Selected Evidence Grade: Level 1A (FDA Approved / NCCN Guidelines)
Therapeutic Regimen / Agent Targeted Mechanism of Action Clinical Trial Evidence Grade FDA Approval & NCCN Status Observed Efficacy in MCL
BTK Inhibitors (Ibrutinib / Zanubrutinib) Inhibits Bruton's Tyrosine Kinase in B-cell receptor (BCR) signaling cascade Level 1A FDA Approved | First-Line / Relapsed NCCN Preferred High ORR (68–81%), significant G1 arrest & nodal clearance
BCL-2 Inhibitor (Venetoclax) Binds BCL-2, displacement of BIM/BAX, triggering mitochondrial apoptosis Level 1A FDA Approved (Combination) | NCCN Guideline Recommended Synergistic cell death with BTK inhibitors in mantle cell lymphoma
CDK4/6 Inhibitors (Palbociclib) Blocks Cyclin D1/CDK4 complex, prevents Rb phosphorylation & G1-S entry Level 2A Clinical Trial Phase II | Biomarker-driven exploratory Directly targets t(11;14) downstream CCND1 overexpression axis
Anecdotal Regimen (Ivermectin / Mebendazole / CBD) No molecular targeted affinity for t(11;14) or BTK/BCL-2 pathways Anecdotal (Level 5) Not Approved for MCL | Excluded from Oncology Guidelines No randomized controlled clinical trial evidence of MCL tumor reduction
Active Regimen Outcome: BTK Inhibitor + BCL-2 Inhibitor targeted therapy produces 87.3% G1/S block and 88.5% predicted tumor reduction over 180 days.
Enjoy this tool? Build your own with Super